Open Trials

Ovary

AGO-OVAR 2.29

Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer – a randomized phase III trial

AGO-OVAR 2.34 / MIROVA

A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible for platinum-based chemotherapy

AGO-OVAR 2.36 / MIRASOL

A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL)

Ovary / Endometrium / Cervix

AtTEnd – Atezolizumab in endometrial carcinoma

A phase III, double-blind, randomized, placebo-controlled trial of the use of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial carcinoma

AGO-EN 3 / RUBY

A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (RUBY)

Surgical issues

AGO-OVAR OP.6 ECLAT

Pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer at high risk of recurrence. A multicenter, prospective randomized controlled trial.